Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | RP-3500 + RP-6306 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| RP-3500 | RP 3500|RP3500|Camonsertib | ATR Inhibitor 16 | RP-3500 binds to and inhibits ATR, which may lead to decreased downstream signaling and inhibition of tumor growth (PMID: 34911817). | |
| RP-6306 | RP6306|RP 6306|Lunresertib | PKMYT1 Inhibitor 4 | RP-6306 is a PKMYT1 inhibitor, which may decrease CDK1 phosphorylation, leading to cell cycle arrest, apoptosis, and decreased tumor growth (Cancer Res (2025) 85 (8_Supplement_2): CT262, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FBXW7 inact mut | endometrial cancer | predicted - sensitive | RP-3500 + RP-6306 | Phase I | Actionable | In a Phase I trial (MYTHIC), treatment with the combination of RP-6306 and RP-3500 in ovarian or endometrial cancer patients harboring CCNE1 amplification, FBXW7 mutations, and/or PPP2R1A mutations resulted in a clinical benefit rate (CBR) of 79%, a median progression-free survival (mPFS) of 21 weeks, and a response rate of 38% in ovarian cancer (n=24), and a CBR of 48%, mPFS of 17 weeks, and a response rate of 26% in endometrial cancer (n=27) (Cancer Res (2025) 85 (8_Supplement_2): CT262; NCT04855656). | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04855656 | Phase I | RP-6306 Debio 0123 + RP-6306 RP-3500 + RP-6306 | Study of RP-6306 Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors (MYTHIC) | Recruiting | USA | GBR | DNK | CAN | 0 |
| NCT05605509 | Phase II | Fluorouracil + Irinotecan + Leucovorin + RP-6306 RP-3500 + RP-6306 RP-6306 + Trastuzumab Gemcitabine + RP-6306 | RP-6306 in Patients With Advanced Cancer | Active, not recruiting | CAN | 0 |